Advances in Therapy

, Volume 23, Issue 5, pp 680–695

Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy

  • R. Fogari
  • A. Zoppi
  • A. Mugellini
  • P. Preti
  • M. Destro
  • A. Rinaldi
  • G. Derosa
Article

DOI: 10.1007/BF02850307

Cite this article as:
Fogari, R., Zoppi, A., Mugellini, A. et al. Adv Therapy (2006) 23: 680. doi:10.1007/BF02850307

Abstract

This study was undertaken to evaluate the effects on blood pressure of hydrochlorothiazide (HCTZ) 12.5 mg added to valsartan 160 mg or to olmesartan 20 mg in hypertensive patients. After a 2-wk placebo period, 130 patients, aged 35 to 75 y, with diastolic blood pressure (DBP) ≥99 and <110 mm Hg were randomly assigned to olmesartan 20 mg once daily or to valsartan 160 mg once daily according to a prospective, parallel-arm study design. After 4 wk of monotherapy, patients whose BP was not controlled (DBP ≥90 mm Hg) were given combination treatment with HCTZ 12.5 mg for an additional 4 wk. At the end of the placebo period and at the end of each treatment period, clinical and ambulatory BP measurements were recorded. At the end of the combination therapy period, venous blood samples were drawn 2, 4, and 24 h after drug intake for evaluation of HCTZ plasma concentrations. Both combinations induced a greater ambulatory BP reduction than monotherapy. However, mean reduction from baseline in the valsartan/HCTZ-treated patients (-21.5/-14.6 mm Hg for 24 h, -21.8/-14.9 mm Hg for daytime, and -20.4/-13.7 mm Hg for nighttime systolic blood pressure [SBP]/DBP) was greater than in the olmesartan/HCTZ-treated patients (-18.8/-12.3 mm Hg for 24 h, -19.3/-12.8 mm Hg for daytime, and -17.4/-10.6 mm Hg for nighttime SBP/DBP). The difference between the effects of the 2 treatments was significant (P<.01). In particular, compared with monotherapy, the add-on effect of HCTZ 12.5 mg was significantly greater in the valsartan group than in those treated with olmesartan; the difference was more evident for nighttime BP values. Plasma concentrations of HCTZ were significantly greater with valsartan than with olmesartan at each determination time (P<.05). These findings suggest that the addition of HCTZ 12.5 mg to valsartan 160 mg monotherapy produces a greater BP reduction than the addition of the same dose of HCTZ to olmesartan 20 mg monotherapy.

Keywords

hydrochlorothiazide valsartan olmesartan hypertension 

Copyright information

© Health Communications Inc 2006

Authors and Affiliations

  • R. Fogari
    • 1
  • A. Zoppi
    • 1
  • A. Mugellini
    • 1
  • P. Preti
    • 1
  • M. Destro
    • 1
  • A. Rinaldi
    • 1
  • G. Derosa
    • 1
  1. 1.Department of Internal Medicine Clinica Medica II IRCCS Policlinico San MatteoUniversity of PaviaPaviaItaly

Personalised recommendations